SCHEMBL5324405

SCHEMBL5324405

NC(Cc1c(I)cc(O)cc1I)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT5 Q9NXA8 1/20 0.59
SLC7A5 Q01650 3/20 0.52
THRB P10828 5/20 0.50
USP2 O75604 4/20 0.50
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
HSD17B10 Q99714 4/20 0.50
LMNA P02545 4/20 0.50
ALOX15 P16050 3/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2C9 P11712 2/20 0.50
ALDH1A1 P00352 2/20 0.50
MAPT P10636 2/20 0.50
NR1H4 Q96RI1 2/20 0.50
HIF1A Q16665 2/20 0.50
KDM4E B2RXH2 2/20 0.50
RECQL P46063 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
PKM P14618 2/20 0.50
PCNA P12004 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5324409 1.00 SIRT5 (0.59) SIRT5SLC7A5THRBUSP2MEN1
SCHEMBL5324396 0.82 SIRT5 (0.54) SIRT5SLC7A5THRBUSP2MEN1
SCHEMBL5324398 0.82 SIRT5 (0.54) SIRT5SLC7A5THRBUSP2MEN1
SCHEMBL1572564 0.80 KDM4E (0.56) SIRT5SLC7A5THRBUSP2MEN1
SCHEMBL31189933 0.80 KDM4E (0.56) SIRT5SLC7A5THRBUSP2MEN1
SCHEMBL1572565 0.80 KDM4E (0.56) SIRT5SLC7A5THRBUSP2MEN1
SCHEMBL10608422 0.79 SLC7A5 (0.50) SIRT5SLC7A5THRBUSP2MEN1
SCHEMBL296690 0.79 SLC7A5 (0.50) SIRT5SLC7A5THRBUSP2MEN1
SCHEMBL296983 0.79 USP2 (0.53) SIRT5SLC7A5THRBUSP2MEN1
SCHEMBL5320524 0.79 SLC7A5 (0.50) SIRT5SLC7A5THRBUSP2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070258899-A1 Diagnostic and therapeutic agents KARYON-CTT LTD (FI) 2007-11-08 US disclosed
WO-2007113385-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS KARYON-CTT LTD (FI) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070258899-A1 Diagnostic and therapeutic agents YBX1, MLX, TPX2 SIRT5 4337/4885SLC7A5 3712/4885THRB 3362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.